Chiron Capital Management LLC Invests $882,000 in Danaher Corporation $DHR

Key Points

• Chiron Capital Management LLC acquired 4,301 shares of Danaher Corporation, valued at approximately $882,000, during the first quarter of 2023.
• Institutional investors own 79.05% of Danaher stock, with several funds like Vanguard and Invesco increasing their positions significantly in the same period.
• Danaher reported better-than-expected quarterly earnings, with an EPS of $1.80 compared to an estimated $1.64, alongside a revenue increase of 3.4% year over year.

Chiron Capital Management LLC bought a new stake in shares of Danaher Corporation (NYSE:DHR - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 4,301 shares of the conglomerate's stock, valued at approximately $882,000.

Several other hedge funds also recently modified their holdings of DHR. Vanguard Group Inc. lifted its holdings in Danaher by 0.4% during the first quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate's stock worth $12,296,123,000 after acquiring an additional 230,966 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of Danaher by 3.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate's stock valued at $4,016,404,000 after purchasing an additional 612,154 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Danaher by 2.3% during the 1st quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate's stock valued at $1,800,614,000 after purchasing an additional 194,466 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Danaher by 11.4% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,677,032 shares of the conglomerate's stock valued at $1,303,163,000 after purchasing an additional 579,046 shares during the last quarter. Finally, Invesco Ltd. increased its position in shares of Danaher by 44.5% during the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock valued at $965,259,000 after purchasing an additional 1,450,703 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on DHR. Barclays reaffirmed an "overweight" rating and set a $225.00 target price (up from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. Guggenheim restated a "buy" rating and issued a $250.00 target price on shares of Danaher in a research note on Wednesday, July 23rd. Wells Fargo & Company lowered their target price on Danaher from $210.00 to $205.00 and set an "equal weight" rating on the stock in a research note on Wednesday, July 23rd. Royal Bank Of Canada set a $241.00 target price on Danaher in a research note on Tuesday. Finally, Deutsche Bank Aktiengesellschaft lowered their target price on Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. Seventeen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $246.35.

Danaher Stock Performance

Shares of NYSE:DHR traded up $1.29 during midday trading on Friday, reaching $200.32. 2,837,584 shares of the company traded hands, compared to its average volume of 2,859,442. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $279.90. The firm has a market capitalization of $143.44 billion, a price-to-earnings ratio of 42.62, a price-to-earnings-growth ratio of 2.79 and a beta of 0.75. The firm's fifty day moving average price is $201.93 and its two-hundred day moving average price is $199.37.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The company had revenue of $5.94 billion for the quarter, compared to analyst estimates of $5.83 billion. During the same period in the previous year, the company posted $1.72 EPS. The firm's revenue for the quarter was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, equities analysts expect that Danaher Corporation will post 7.63 earnings per share for the current year.

Insiders Place Their Bets

In other Danaher news, Director Teri List sold 2,778 shares of the company's stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the transaction, the director directly owned 20,751 shares in the company, valued at $4,379,706.06. This represents a 11.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 11.10% of the stock is owned by corporate insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.